LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc., the global leader in non-invasive molecular dermatology, announced it has received permitting from the State of New York, Department of Public Health. The addition of a New York permit to DermTech’s current accreditations, allows it to now provide laboratory services across the United States in all 50 states and the District of Columbia.
“We are proud to receive the New York CLEP accreditation to support New York’s melanoma skin cancer testing needs” said Darryl Garrison, DermTech’s Vice President of Operations. “Clinical labs receiving New York lab accreditation go through a detailed NY lab inspection as well as individual assay approval in order to receive this highly sought after license.”
"We are excited to join a select group of clinical laboratories that possess licensure from the State of New York," said DermTech’s Chief Executive Officer, John Dobak, MD. "Receiving this accreditation is a critical achievement, enabling us to provide molecular pathology services to dermatologist and dermatopathologists across the country."
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit dermtech.com.